Navigation Links
BioBDx to Present at the 2011 BioPharm America Conference
Date:8/31/2011

PLYMOUTH MEETING, Pa., Aug. 31, 2011 /PRNewswire/ -- BioBDx announced today that the Company's Chairman and CEO Byron Hewett will present at the 2011 BioPharm America Conference taking place September 7-9.  BioBDx manufactures and markets the Quotient® System, a tool that objectively measures brain functions related to deficits in response inhibition. The first FDA-cleared application of this platform technology is objective measurement of hyperactivity, impulsivity and inattention as an aid in the assessment of attention-deficit hyperactivity disorder (ADHD).  Mr. Hewett will provide a company overview and update on the Quotient ADHD System on Thursday, September 8 at 4:15 p.m. EDT in the Otis room at the Westin Boston Waterfront Hotel in Boston, MA.

About the Quotient® ADHD TestThe Quotient® ADHD Test measures motion and analyzes shifts in attention state to give an objective picture of the core symptom areas of ADHD.  Clinicians use the Quotient® ADHD Test at the initial visit to assess severity of the three core symptoms of ADHD; hyperactivity, inattention and impulsivity.  Patients may be re-assessed periodically at follow-up visits to guide treatment plans.  The clinician integrates the Quotient® ADHD Test report with information from other assessment tools and the clinical evaluation to help guide the discussion on the treatment plan. For more information about the Quotient® ADHD System, please visit http://www.biobdx.com/products

About BioBehavioral Diagnostics CompanyBioBDx manufactures and markets the Quotient System, a tool that aids in the objective and accurate assessment of neural control functions related to deficits in inhibitory control.  We are dedicated to providing physicians, parents and patients with high-value information to guide personalized strategies and to enhance quality of life for patients with ADHD. &
'/>"/>

SOURCE BioBDx
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
3. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
4. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
5. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
8. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
9. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
10. New Study Presented at WorldSleep 2007 Demonstrates Ramelteon Has Sustained Efficacy Over Six Months in Adults With Chronic Insomnia
11. ViroPharma to Present at Three Upcoming Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... , May 20, 2013 Hyland ... healthcare industry by creating the Multi-Disciplinary Clinical Leadership ... variety of medical experts with diverse healthcare experience, ... healthcare industry to create new software solutions that ... specific needs of patients and staff. ...
(Date:5/20/2013)... 20, 2013 Enrollment of patients with Type ... dose-finding clinical trial of product candidate NewMet ™, ... for Type 2 diabetes. Elcelyx expects to complete enrollment ... June. Results of the trial,s primary endpoint of change ... and the read-out for long-term glucose lowering and weight ...
(Date:5/20/2013)...  Rhythm announced today the presentation of results from ... gastroparesis symptoms among diabetic patients in the U.S. than ... patients with both type 1 and type 2 diabetes, ... the more common type 2 disease. ... Professor of Medicine at Harvard Medical School and Director ...
Breaking Medicine Technology:Hyland Software Forms Multi-Disciplinary Clinical Leadership Team to Augment Healthcare Solutions 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 2Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 3Elcelyx Therapeutics Enrolling Phase 2b Trial of NewMet for Type 2 Diabetes 4Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 2Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 3Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S. 4
(Date:5/20/2013)... University of Southampton has shown that blind and visually ... to that used by bats and dolphins, to determine ... is published in the journal Hearing Research , ... could help blind people with spatial awareness and navigation. ... impairment and how to optimise echolocation ability in order ...
(Date:5/20/2013)... 6Webs.com is the leading supplier of ... 6Webs.com recently completed their assessments of the top alarm ... annually and the top home security system companies are ... technology, equipment and warranties to mention a few. ... team completed the home security reviews, numerous people claimed ...
(Date:5/20/2013)... Dermatologists are saying that new federally mandated labeling ... choices when it comes to products that provide ... required by the U.S. Food and Drug Administration ... will protect against skin cancer in addition to ... a sunscreen is water-resistant, according to the American ...
(Date:5/20/2013)... VHA Inc., the national health care ... population health improvement, announced a new offering to ... pursue population health management with a strategic ... the transition to value-based models of care. As ... of services, the offering integrates VHA expert advisory ...
(Date:5/20/2013)... Researchers at Lund University in Sweden have mapped ... atherosclerotic disease. No studies have previously examined whether ... study looked at coronary heart disease, ischemic stroke, ... in individuals whose siblings and parents have suffered ... showed that heredity is highest for atherosclerosis of ...
Breaking Medicine News(10 mins):Health News:New study finds blind people have the potential to use their 'inner bat' to locate objects 2Health News:Best Home Alarm System Companies in 2013 Published by Leading Security Reviews Site - 6Webs.com 2Health News:Revised Sunscreen Labels Should Help Consumers Make Wiser Choices 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 2Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 3Health News:VHA Partners with Phytel to Add Population Health Management Services to the VHA IMPERATIVTM Performance Improvement Suite of Offerings 4
... MKL ) reported diluted net loss per share ... to diluted net income per share of $9.26,for the ... was $2.63 for the,nine months ended September 30, 2008 ... the same period of 2007. The results for both ...
... more targeted prevention efforts, researcher says , , TUESDAY, Nov. 4 ... Hispanics in the United States, a new study shows. , ... a type of beverage that is more associated with risky ... developed to target that beverage and that type of drinking," ...
... HAVEN, Conn., Nov. 4 VION,PHARMACEUTICALS, INC. (OTC Bulletin ... on Thursday, November 6, 2008 to,discuss its 2008 third ... 8:30 a.m. Eastern Time., To participate in the ... 213-8858 for international callers), at least 15 minutes,before the ...
... 4, 2008 Proactive measures can reduce hip fracture rates ... as 50 percent -- among those at risk, according to ... was published online on November 3 by The Journal ... , The largest study of its kind, the five-year study ...
... be Held at 8 a.m. EST -, SHENZHEN, ... (NYSE: NPD ) ("China Nepstar" or the "Company"), ... of directly operated,stores, announced today that the Company will ... before the market opens on,Wednesday, November 26, 2008., ...
... (Nasdaq: IRIX ) today reported financial results for ... the third quarter of 2008 was $12.0 million, an ... quarter of 2007. The,Company recorded net loss of $0.2 ... of 2008, an improvement over the net loss of ...
Cached Medicine News:Health News:Markel Reports Third Quarter and Nine-Month Results 2Health News:Markel Reports Third Quarter and Nine-Month Results 3Health News:Markel Reports Third Quarter and Nine-Month Results 4Health News:Study Shows Hispanics Prefer Beer 2Health News:Vion Updates Conference Call Information 2Health News:Vion Updates Conference Call Information 3Health News:Healthy bones program reduces hip fractures by 37 percent 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 2Health News:China Nepstar Chain Drugstore to Announce Third Quarter 2008 Financial Results on November 26 3Health News:IRIDEX Reports Third Quarter 2008 Financial Results 2Health News:IRIDEX Reports Third Quarter 2008 Financial Results 3Health News:IRIDEX Reports Third Quarter 2008 Financial Results 4Health News:IRIDEX Reports Third Quarter 2008 Financial Results 5Health News:IRIDEX Reports Third Quarter 2008 Financial Results 6
... IMMULITE 1000 assays are designed ... and IMMULITE 1000, continuous random ... simplicity in both design and ... found in a wide variety ...
... Digoxin Assay is a homogeneous ... in the quantitative analysis of ... plasma. Kits are packaged specifically ... COBAS MIRA, COBAS MIRA S, ...
The Emit 2000 Digoxin Assay is a homogeneous enzyme immunoassay for use in the quantitative analysis of digoxin in human serum or plasma. Kits are conveniently packaged in Olympus Reagent Cartridges ...
Liquichek Rheumatoid Factor Control is a liquid trilevel control designed to monitor rheumatoid factor testing procedures, including nephelometric and latex agglutination methods....
Medicine Products: